Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991).1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD.1 The Phase III trial will enroll adults with symptomatic COPD who continue to experience exacerbations and have blood eosinophil counts below 300 cells/µL.1 Ingelheim, Germany and Ridgefield, Conn., U.S. […]
Boehringer Ingelheim has registered a Phase III trial for its investigational oral therapy, verducatib, which aims to target DPP1 in adults with COPD. The trial, known as AIRWARD™, will evaluate the effectiveness of verducatib in individuals who continue to experience exacerbations despite standard treatment and have a blood eosinophil count below 300 cells/µL.
Boehringer Ingelheim, with over 100 years of experience in respiratory medicine, is committed to addressing the needs of patients who still experience exacerbations while receiving standard care. The trial has been published on ClinicalTrials.gov under the identifier NCTXXXXXX.
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
